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Abstract
Purpose: Physical inactivity, in addition to clinical factors, has been associated with higher levels of late pelvic symptoms in patients
with prostate cancer (PCa) after radiation therapy. The aim of this study was to investigate the effect of a structured multicomponent
exercise program comprised of aerobic and resistance training as well as impact loading on the prevalence and severity of symptoms
commonly resulting from androgen deprivation therapy (ADT) and pelvic radiation therapy.
Methods and Materials: We performed a secondary analysis of pooled data from 2 randomized controlled trials that investigated the
role of exercise on treatment-related side effects in patients with PCa receiving ADT. Patients were included in the analysis if they had
undergone radiation therapy during the intervention in addition to ADT. Patient-reported quality of life and functional and symptom
scales were assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 and PR25 before and after 6
months of exercise or usual care (UC).
CME
Sources of support: The original studies upon which this secondary analysis is based were funded by the National Health and Medical Research
Council, Australia (NHMRC; grant number 534409), the Prostate Cancer Foundation of Australia, Australia, the Cancer Council Western Australia,
Australia, and the Cancer Council Queensland, Australia (for ref.14) as well as Cancer Australia, the Prostate Cancer Foundation of Australia and Beyond
Blue (NHMRC grant number 1029901 (for ref.15). O.S. is supported by a PhD scholarship from the NHMRC Centre of Research Excellence in Prostate
Cancer Survivorship. The sponsors had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report;
and in the decision to submit the article for publication.
Disclosures: Drs Newton, Galvão, Taaffe, Joseph, and Spry report grants from National Health and Medical Research Council (NHMRC), grants from
Prostate Cancer Foundation of Australia, grants from Cancer Council of Western Australia, grants from Cancer Council of Queensland, grants from
Cancer Australia, grants from Beyond Blue during the conduct of the study. Oliver Schumacher received a PhD scholarship from the NHMRC Centre of
Research Excellence in Prostate Cancer Survivorship. Drs Tang and Chee have nothing to disclose.
Data sharing statement: Research data are not available at this time.
NoteeAn online CME test for this article can be taken at https://academy.astro.org.
* Corresponding author: Robert U. Newton, PhD; E-mail: r.newton@ecu.edu.au
https://doi.org/10.1016/j.prro.2021.01.005
1879-8500/ 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Practical Radiation Oncology® (2021) 11, 215-225
www.practicalradonc.org
Results: One-hundred and fifteen patients with PCa receiving ADT, aged 47 to 84 years, who also underwent radiation therapy were
included in the analysis (exercise, n Z 72; UC, n Z 43). There was a significant reduction in physical functioning (P Z .019) and
increased fatigue (P Z .007) in the control group, with no change observed in the exercise group. Similarly, there was a trend toward
reduced sexual activity in the control group (P Z .064), with a mean adjusted change of -7.1 points. Furthermore, the prevalence of
clinically important pain at 6 months was lower in the exercise group compared with UC (18.1 vs 37.2%, PZ .022). No between-group
differences were found for urinary (P Z .473) or hormonal treatment-related symptoms (P Z .552).
Conclusions: Exercise during concomitant hormone and radiation treatment for men with PCa may mitigate some adverse changes in
patient-reported fatigue, physical functioning, and possibly sexual activity. The promotion and provision of exercise to counter a range
of treatment-related adverse effects in patients with PCa undergoing radiation therapy and ADT should be actively encouraged.
 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Prostate cancer is among the most prevalent cancers
globally and the second most commonly diagnosed cancer
in males after lung cancer.1 In 2018, an estimated 1,276,106
new cases of prostate cancer were diagnosed and 358,989
deaths were recorded.1 Approximately 37% to 42% of pa-
tients with prostate cancer aged 65 years and older receive
radiation therapy as their initial treatment.2 Based on the
severity of the disease, some patients may receive radiation
therapy in combination with androgen deprivation therapy
(ADT).3 Over the past few decades, technological advances
and improved treatment regimens have led to increased
tumor control and a dramatic reduction in radiation therapy
toxicity.4 However, despite modern treatment techniques,
some patients still experience adverse effects from radiation
therapy.4 Although patients are surviving longer, health-
related quality of life is negatively affected as a result of
long-term consequences of radiation therapy as well as late
treatment-associated toxicity.4
Adverse effects associated with pelvic radiation therapy
of the prostate commonly encompass urinary and bowel
symptoms, including rectal toxicity, as well as reduced
sexual function. Symptoms exacerbate over the course of
treatment, are most severe immediately after radiation
therapy, and generally improve thereafter.5,6 Furthermore,
clinical factors such as a higher prescribed radiation dose,
preexisting bladder and bowel symptoms, as well as older
age have been associated with increased late-onset toxicity
after pelvic radiation therapy in men with prostate cancer.6,7
Lifestyle factors including cigarette smoking as well as
being overweight or obese have also been associated with
increased toxicity after treatment in this patient group.8-10
In addition, physical inactivity during and after radiation
therapy has been associated with more severe late pelvic
symptoms.10 Conversely, increasing bowel symptoms have
been associated with a reduced likelihood of being physi-
cally active (ie, exercising 2 or more times per week)
following treatment.11
Exercise has been shown to reduce treatment-related
adverse effects such as loss of muscle and bone mass,
fatigue, and decline in physical function associated with
ADT in men with prostate cancer.12-15 Moreover, pelvic
floor training programs have been effective in reducing the
duration of incontinence after radical prostatectomy.16 In
contrast, relatively few studies have investigated the effect
of concomitant exercise during treatment on acute
radiation-induced toxicity in men with prostate cancer.
Kapur et al17 performed a retrospective analysis of acute
radiation toxicity in 65 men with localized prostate cancer
who had participated in a randomized controlled trial of
aerobic exercise (ie, home-based continuous walking for 30
minutes at least 3 days a week at a moderate intensity; n Z
32) during 4 weeks of radiation therapy. Although rectal
toxicity was not significantly different between groups at
weekly assessment time points during treatment, the mean
rectal toxicity scores over the 4-week treatment period were
significantly lower in the exercise group.17 Furthermore,
mean bladder toxicity scores were significantly lower in the
exercise group at 4 weeks post radiation therapy comple-
tion.17 There can be hesitancy among clinicians to recom-
mend exercise,18,19 in particular resistance or impact
training, due to concerns about exacerbating urinary and
bowel issues; however, this has not been reported in the
scientific literature and appears anecdotal.
Given the paucity of current evidence regarding the
influence of exercise training on radiation-induced
toxicity in men with prostate cancer, we performed a
secondary analysis of 2 randomized controlled trials and
investigated the effect of a structured multicomponent
exercise program that contained aerobic and resistance
training as well as impact loading on the prevalence and
severity of symptoms commonly resulting from radiation
therapy and ADT in men with prostate cancer.
Methods and Materials
We performed a secondary analysis on pooled data from
2 randomized controlled trials that investigated the conse-
quence of exercise on treatment-related side effects in men
with prostate cancer receiving ADT with or without
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concurrent radiation therapy.14,15 In short, a total of 258
men undergoing treatment for prostate cancer were
recruited across both studies by referral from their treating
urologist or radiation oncologist in Perth, Western
Australia. Detailed inclusion and exclusion criteria for these
studies are described elsewhere.14,15 For the current anal-
ysis, patients were included if they had commenced radi-
ation therapy during the course of the initial 6 months of
the intervention and had complete questionnaire response
rate (ie, it was possible to calculate scales/scores after
imputing missing items) at baseline and after 6 months of
the exercise intervention or usual care (Fig 1). Both studies
were approved by the Human Research Ethics Committee
at Edith Cowan University and all participants provided
written informed consent (Clinical Trial Registry Number:
ACTRN12609000200280 and ACTRN12612000097842).
Study design
In Newton et al,14 patients were randomly allocated to
1 of 3 groups: (1) impact loading þ resistance training,
(2) aerobic exercise þ resistance training, or (3) usual care
þ delayed exercise. Group (3) acted as a control group
and commenced aerobic exercise after 6 months of the
intervention. In Taaffe et al,15 patients were randomized
to either an immediate exercise group that undertook a
multicomponent exercise program consisting of aerobic,
resistance, and impact-loading exercises for 6 months or a
delayed exercise group that received usual care for the
initial 6 months of the intervention (control) followed by
6 months of the identical exercise program as the imme-
diate exercise group. The studies by Newton et al14 and
Taaffe et al15 were both yearlong trials; however, for the
purpose of the current analysis, patients were grouped
into exercise versus usual care (control) based on whether
they engaged in the structured exercise program during
the initial 6 months of the intervention. Accordingly, only
study outcome measures reported at baseline and at 6
months were assessed in this analysis.
Exercise program
A detailed description of the exercise interventions of
both source data sets has been published elsewhere.14,15
Patients included in analysis
(n=115)
Patients assessed for eligibility
(n=258)
Newton et al. 2019 Taaffe et al. 2019
Patients enrolled in original
study
(n=154)











Imputation for EORTC QLQ-C30
and PR25 not possible (n=13)
Patients in exercise groups
(n=43)
Patients in control group
(n=18)
Patients in exercise group
(n=29)
Patients in control group
(n=25)
Patients allocated to exercise group for secondary analysis
(n=72)




Imputation for EORTC QLQ-C30
and PR25 not possible (n=8)
Figure 1 Study flow diagram.
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Briefly, exercise was undertaken 2 to 3 days per week in
small groups of up to 10 patients in an exercise clinic
setting with supervision by accredited exercise physiolo-
gists and performed at a moderate to high intensity.
Specifically, resistance training consisted of 6 primary
exercises targeting the major upper and lower body
muscles (ie, chest press, seated row, shoulder press, leg
press, leg extension, and leg curl) that were supplemented
with the lat pull down, biceps curl, triceps extension, and
seated calf raise. Exercises were performed for 2 to 4 sets
each at an intensity of 6- to 12-repetition maximum (RM)
with a 1 to 2 minute rest period between sets. Aerobic
exercise was performed for 20 to 40 minutes at an in-
tensity of 60% to 85% of maximal heart rate (HRmax) and
consisted of different exercise modes, including walking/
jogging on a treadmill and cycling or rowing on a sta-
tionary ergometer. Exercise intensity was monitored using
individual HR monitors with a chest strap (Polar Electro
Oy, Kempele, Finland) and adjusted to maintain HR
within the target range. At later stages of the program,
some sessions included interval training with intensities
up to 85% of HRmax to reduce potential boredom. Impact
loading consisted of 2 to 4 rotations of skipping (30
seconds), bounding over soft hurdles (13-30 cm), drop
jumps (10-20 cm), and hopping/leaping (10 repetitions
per set). In addition to clinic-based training, patients in the
impact loading þ resistance training group performed
home-based exercises consisting of 2 to 4 rotations of
skipping (30 seconds), hopping, leaping, and drop
jumping (10 repetitions each) 2 days/week. Patients in the
aerobic exercise þ resistance training group were
encouraged to accumulate an additional 150 minutes/
week of home-based aerobic activity. Similarly, patients
who undertook the multicomponent exercise program
consisting of aerobic exercise, resistance training, and
impact-loading were encouraged to perform additional
twice weekly home-based aerobic exercise activities such
as walking or cycling and a modified version of the
impact loading program. All clinic-based sessions
commenced with a warm-up consisting of low intensity
aerobic exercise and ended with a cool-down comprised
of stretching exercises.
Primary endpoints
Quality of life and functional and symptom scales were
assessed at baseline and after 6 months of exercise or
usual medical care using the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire core (QLQ-C30) and prostate cancer
(PR25) module.20,21 Scores for each scale are calculated
based on either a single or multiple items of the ques-
tionnaire, where higher scores indicate better functioning
or more symptom burden and lower scores indicate worse
functioning or less symptom burden. Missing items (ie, 1
or more missing answers to questions within a question-
naire) from multi-item scales were imputed if at least half
of the items from the scale had been answered. Specif-
ically, it was assumed that the missing items had values
equal to the average of those items that were present for
that respondent.22 To calculate the prevalence of clinically
important problems/symptoms for each EORTC QLQ-
C30 scale, we used the thresholds for clinical impor-
tance determined by Giesinger et al.23
Other measures
Demographic and clinical patient data were collected
by self-report and extracted from medical records,
respectively. Height and weight were assessed using a
stadiometer and electronic scale, respectively, to subse-
quently calculate body mass index (BMI) as kg/m2.
Physical activity levels were assessed using the Godin
leisure-time exercise questionnaire.24 Prostate-specific
antigen and testosterone were measured by an Austra-
lian National Association of Testing Authorities labora-
tory (Pathwest Diagnostics, Perth, WA, Australia). A
physical performance battery consisting of 400-meter
walk, repeated chair rise test, and backward 6-meter
walk was used to assess walking endurance, lower body
strength, and dynamic balance, respectively.25 In addition,
1RM muscle strength testing was performed for the chest
press, leg press, and seated row exercises.25
Statistical analysis
Data were analyzed using IBM SPSS Statistics version
25 (IBM Corp, Armonk, NY). For continuous variables,
normality of the distribution was assessed using the
Shapiro-Wilk test. Patient characteristics at baseline were
analyzed using independent t tests or Mann-Whitney U
tests, as appropriate, for continuous data and c2 tests for
categorical data to assess any between-group differences.
Generalized linear mixed models were performed for each
EORTC QLQ-C30 and PR25 scale as well as for physical
performance variables with patient as random effect and
BMI, hypertension status (ie, yes or no), time (ie, baseline
or 6 months), and group (ie, exercise or control) as fixed
effects. For post hoc pairwise contrasts the sequential
Bonferroni adjusted significance level was 0.05. Between-
group differences for prevalence rates of clinically
important problems/symptoms for each EORTC QLQ-
C30 scale at baseline and 6 months were analyzed using
c2 tests. All tests were 2-tailed and statistical significance
was set at an a level of 0.05 for all analyses.
Results
Patient demographic and clinical characteristics for
the 115 men included in the analyses are shown in
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Table 1. There were no significant differences between
the exercise (n Z 72) and control group (n Z 43) in
baseline characteristics, except for BMI and hyperten-
sion, with patients in the control group having a higher
BMI and a higher prevalence of hypertension compared
with the exercise group. Men were aged 47 to 84 years
and had a median Gleason score of 7. The median
duration of radiation therapy that was completed within
the 6-month intervention was 45.5 days, and patients
commenced radiation therapy treatment a median of 98
days after their baseline assessments. Two men had an
interruption of their radiation therapy treatment. There
were no major exercise-related adverse events in either
exercise trial.
Physical performance outcome
Exercise had the desired effect, with a significant dif-
ference between the exercise and control groups in
walking endurance as assessed by 400-meter walk time (P
Z .039), with an adjusted mean difference of -10.2 sec-
onds (Table 2). Furthermore, significant between-group
differences in 1RM strength were observed for the chest
press (P < .001), leg press (P < .001), and seated row (P
Z .002), with all strength measures increasing in the
exercise group from baseline to 6 months while
decreasing in the control group. There were no between-
group differences for the repeated chair rise time and the
backward 6-meter walk time.
Table 1 Demographic and clinical characteristics of patients in the exercise and control group at baseline
Exercise group (n Z 72)* Control group (n Z 43)* P value
Age (years), mean (SD) 67.9 (7.8) 67.8 (7.5) .937
Height (cm), mean (SD) 172.9 (6.4) 171.6 (5.7) .275
Weight (kg), median (IQR) 80.5 (71.4-92.2) 83.1 (75.3-95.2) .094
BMI (kg/m2), median (IQR) 26.9 (24.7-29.5) 28.6 (25.9-33.2) .012
Married, n (%) 58 (81.7)y 37 (86.0) .545
Currently employed, n (%) 26 (36.1) 19 (44.2) .391
Tertiary education, n (%) 22 (31.0)y 9 (20.9) .242
Current smoker, n (%) 4 (5.6) 2 (4.7) .833
Gleason score, median (IQR) 7.0 (7.0-8.5)z 7.0 (7.0-8.0)x .666
PSA (ng/mL), median (IQR) 0.5 (0.0-2.3)k 0.7 (0.1-2.9){ .256
Testosterone (nmol/L), median (IQR) 1.1 (0.0-3.1)k 1.7 (0.7-4.4){ .179
Godin leisure-time activity score,
median (IQR)
24.0 (13.0-36.0)y 25.5 (17.3-45.0){ .490
Cardiovascular disease, n (%) 6 (8.3) 6 (14.0) .340
Hypertension, n (%) 24 (33.8)y 23 (54.8){ .029
Dyslipidemia, n (%) 19 (26.4) 18 (42.9){ .070
Diabetes, n (%) 10 (13.9) 9 (20.9) .325
EBRT completed within 6-month
intervention (days#), median (IQR)
47.0 (39.5-53.0)k 44.5 (35.0-51.3){ .410
Total EBRT completed (days#),
median (IQR)
50.0 (41.8-53.0)k 50.0 (42.0-52.3){ .864
Baseline to start of radiation therapy
(days), median (IQR)
98.0 (69.0-129.0)y 97.0 (71.0-132.0) .981
End of radiation therapy to follow-up**
,yy
(days), median (IQR)
42.0 (8.5-88.8)k 33.0 (0.0-74.0) .213
Brachytherapy, n (%) 16 (22.2) 9 (20.9) .871
Abbreviations: BMIZ body mass index; EBRTZ external beam radiation therapy; IQRZ interquartile range; PSAZ prostate-specific antigen; SD
Z standard deviation.
* Unless indicated otherwise.
y n Z 71
z n Z 61
x n Z 39
k n Z 70
{ n Z 42
# Days s fractions.
** If radiotherapy ended after the 6-month (ie, follow-up) assessment was completed, the value was set to 0 days difference for that patient.
yy If patient received brachytherapy in addition to EBRT, the date of brachytherapy seed insertion was used as the end of radiotherapy.
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Quality of life outcomes
There were no significant between-group differences
for any of the functional and symptoms scales of the
EORTC QLQ-C30 after exercise (Table 3). However,
there was a significant reduction in physical functioning
(P Z .019) as well as increased fatigue (P Z .007) in the
control group. In addition, diarrhea significantly increased
only in the exercise group (P < .001) compared with a
nonsignificant increase in the control group (P Z .084).
The prevalence rates of clinically important problems/
symptoms ranged from 1.4% (appetite loss) to 39.5%
(dyspnoea) across all scales (Table 4). There was a sig-
nificant between-group difference for clinically important
pain at 6 months that was not observed at baseline, with
pain being more prevalent in the control group compared
with the exercise group (37.2% vs 18.1%, P Z .022).
Similarly, the prevalence of clinically important dyspnoea
increased by ~12% in the control group, whereas it
increased by only ~1% in the exercise group (P Z .070
for between-group difference at 6 months).
Urinary and bowel toxicity
Scores for urinary, bowel, and hormonal treatment-
related symptoms increased (ie, worsened) from baseline
to 6 months in both groups, with no significant difference
between exercise and control (Table 5). However, there
was a trend for exercise to reduce any problems associ-
ated with wearing an incontinence aid compared with the
control group (P Z .056), with an adjusted mean differ-
ence of 21.7 points.
Sexual activity and function
There was no significant difference between groups in
sexual activity, but exercise seemed to ameliorate the
decline in sexual activity that was seen in the control
group (P Z .064), resulting in a mean adjusted within-
group change of -7.1 points (Table 5). No significant
between-group change was observed in sexual func-
tioning between the exercise and control group.
Discussion
We investigated the effects of 6 months of supervised
multicomponent exercise programs on patient-reported
treatment toxicity in men with prostate cancer undergoing
concomitant radiation and ADT. As such, this study
produced 3 important findings: (1) exercise mitigated
some adverse effects of treatment on fatigue, physical
functioning, and possibly sexual activity; (2) the preva-
lence of clinically important pain at 6 months was lower
in the exercise group compared with the usual care control
Table 2 Physical performance measures at baseline and after 6 months of exercise or usual care (control)
Baseline 6 months Estimated mean change from
baseline to 6 months
Adjusted between-group difference
in mean change from baseline to 6
months*
Mean (SD) Mean (SD) Mean (95% CI) P valuey Coefficient 95% CI P value
400-meter walk time (s) e10.2 e19.9 to e0.5 .039
Exercise (n Z 70) 254.2 (38.6) 243.3 (30.5) e10.8 (e16.7 to e5.0) <.001
Control (n Z 40) 256.6 (38.0) 257.4 (40.6) e0.7 (e8.4 to 7.1) .866
Repeated chair rise time (s) e0.4 e1.1 to 0.3 .232
Exercise (n Z 70) 11.9 (2.4) 11.0 (2.4) e0.9 (e1.3 to e0.9) <.001
Control (n Z 40) 12.0 (2.7) 11.6 (2.2) e0.5 (e1.0 to 0.04) .072
Backward 6-meter walk time (s) e1.3 e3.2 to 0.6 .190
Exercise (n Z 70) 16.0 (5.9) 14.7 (4.8) e1.3 (e2.4 to e0.1) .035
Control (n Z 41) 16.0 (5.7) 16.0 (7.3) 0.03 (e1.5 to 1.6) .971
Chest press 1RM (kg) 5.0 3.0-7.0 <.001
Exercise (n Z 67) 39.6 (11.2) 41.9 (11.3) 2.2 (0.9-3.4) .001
Control (n Z 40) 45.6 (14.4) 42.7 (12.5) e2.9 (e4.4 to e1.3) .001
Leg press 1RM (kg) 29.1 18.0-40.3 <.001
Exercise (n Z 69) 128.5 (47.0) 157.4 (54.1) 28.9 (22.2-35.5) <.001
Control (n Z 38) 138.2 (52.9) 137.6 (47.1) e0.3 (e9.2 to 8.7) .955
Seated row 1RM (kg) 6.7 3.6-9.7 <.001
Exercise (n Z 68) 72.3 (14.0) 75.9 (14.0) 3.5 (1.7-5.4) <.001
Control (n Z 40) 75.2 (14.4) 72.0 (11.1) e3.2 (e5.6 to e0.7) .011
Abbreviations: BMI Z body mass index; CI Z confidence interval; RM Z repetition maximum; SD Z standard deviation.
* Generalized linear mixed model analysis adjusted for BMI and hypertension status.
y Estimated mean change and corresponding P values are based on adjusted mixed model analysis using a sequential Bonferroni adjusted sig-
nificance level of 0.05.
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Table 3 EORTC QLQ-C30 global health status and functional and symptoms scales at baseline and after 6 months of exercise or
usual care (control)
Baseline 6 months Estimated mean change from
baseline to 6 months
Adjusted between-group difference in
mean change from baseline to 6
months*
Mean (SD) Mean (SD) Mean (95% CI) P valuey Coefficient 95% CI P value
Global health status 3.8 e1.6 to 9.3 .169
Exercise 78.6 (16.8) 79.5 (15.4) 1.1 (e2.3 to 4.4) .533
Control 73.8 (18.1) 70.7 (21.5) e2.8 (e7.1 to 1.6) .208
Physical functioning 2.7 e0.8 to 6.2 .124
Exercise 94.4 (9.2) 94.0 (10.2) e0.6 (e2.7 to 1.5) .589
Control 89.1 (13.4) 85.3 (17.8) e3.3 (e6.1 to e0.6) .019
Role functioning e4.8 e12.1 to 2.5 .196
Exercise 92.1 (15.1) 89.4 (17.1) e2.8 (e7.3 to 1.6) .213
Control 83.3 (24.7) 85.3 (21.6) 2.0 (e3.8 to 7.8) .499
Emotional functioning 4.1 e1.5 to 9.8 .149
Exercise 88.1 (15.7) 89.8 (14.1) 2.0 (e1.5 to 5.4) .263
Control 84.4 (16.1) 82.4 (20.4) e2.2 (e6.6 to 2.3) .337
Cognitive functioning 2.1 e2.9 to 7.0 .411
Exercise 87.5 (14.7) 87.0 (14.9) e0.7 (e3.7 to 2.3) .646
Control 82.2 (16.8) 79.1 (17.9) e2.8 (e6.7 to 1.2) .165
Social functioning e2.3 e10.0 to 5.3 .548
Exercise 88.9 (18.8) 86.1 (19.2) e2.3 (e7.0 to 2.3) .325
Control 79.5 (21.8) 79.5 (24.9) e0.00 (e6.1 to 6.1) 1.000
Fatigue e5.5 e12.3 to 1.3 .111
Exercise 21.6 (18.9) 23.5 (18.4) 1.9 (e2.3 to 6.0) .374
Control 24.8 (21.1) 32.0 (24.8) 7.4 (2.0-12.8) .007
Nausea and vomiting e0.7 e3.9 to 2.4 .660
Exercise 2.1 (7.4) 1.4 (5.4) e0.7 (e2.6 to 1.2) .470
Control 2.3 (5.8) 2.3 (6.9) e0.00 (e2.5 to 2.5) 1.000
Pain e2.8 e9.8 to 4.2 .430
Exercise 8.8 (13.7) 10.6 (17.8) 2.3 (e1.9 to 6.6) .280
Control 13.6 (18.6) 18.6 (19.7) 5.2 (e0.4 to 10.7) .069
Dyspnoea e3.5 e10.9 to 3.9 .354
Exercise 7.9 (15.3) 8.8 (17.7) 0.5 (e4.1 to 5.0) .838
Control 11.6 (20.4) 17.1 (23.4) 4.0 (e1.9 to 9.9) .185
Insomnia e2.1 e11.9 to 7.6 .668
Exercise 21.3 (25.2) 25.9 (29.2) 4.2 (e1.7 to 10.2) .162
Control 21.7 (24.0) 27.9 (29.9) 6.3 (e1.4 to 14.1) .106
Appetite loss 0.9 e5.5 to 7.4 .773
Exercise 2.3 (10.2) 3.7 (14.3) 0.9 (e3.0 to 4.9) .637
Control 3.9 (13.0) 3.9 (13.0) e0.00 (e5.1 to 5.1) 1.000
Constipation 2.1 e5.9 to 10.0 .611
Exercise 6.9 (16.7) 7.4 (17.0) 0.5 (e4.4 to 5.3) .849
Control 11.6 (25.1) 9.3 (21.0) e1.6 (e7.9 to 4.7) .620
Diarrhea 4.6 e2.2 to 11.4 .182
Exercise 2.3 (10.2) 12.0 (20.4) 9.4 (5.2-13.5) <.001
Control 5.4 (17.7) 10.1 (20.0) 4.8 (e0.6 to 10.2) .084
Financial difficulties 0.3 e6.5 to 7.2 .926
Exercise 7.9 (16.3) 8.3 (19.2) e0.5 (e4.7 to 3.7) .825
Control 13.2 (25.3) 12.4 (25.2) e0.8 (e6.2 to 4.6) .774
Abbreviations: BMI Z body mass index; CI Z confidence interval; EORTC QLQ-C30 Z European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire core; SD Z standard deviation.
Exercise group n Z 72, control group n Z 43.
* Generalised linear mixed model analysis adjusted for BMI and hypertension status.
y Estimated mean change and corresponding P values are based on adjusted mixed model analysis using a sequential Bonferroni adjusted sig-
nificance level of 0.05.
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Table 4 Prevalence of clinically important problems/symptoms for each EORTC QLQ-C30 scale at baseline and after 6 months of
exercise or usual care (control)
Baseline, n (%) 6 months, n (%)
Exercise group Control group P value Exercise group Control group P value
Functioning scales
Physical functioning 7 (9.7%) 11 (25.6%) .024 7 (9.7%) 12 (27.9%) .011
Role functioning 3 (4.2%) 5 (11.6%) .128 5 (6.9%) 5 (11.6%) .388
Emotional functioning 9 (12.5%) 11 (25.6%) .073 8 (11.1%) 7 (16.3%) .426
Cognitive functioning 11 (15.3%) 14 (32.6%) .030 11 (15.3%) 15 (34.9%) .015
Social functioning 4 (5.6%) 7 (16.3%) .059 3 (4.2%) 4 (9.3%) .265
Symptom scales
Fatigue 9 (12.5%) 8 (18.6%) .372 10 (13.9%) 10 (23.3%) .200
Nausea and vomiting 6 (8.3%) 6 (14.0%) .340 5 (6.9%) 5 (11.6%) .388
Pain 13 (18.1%) 10 (23.3%) .500 13 (18.1%) 16 (37.2%) .022
Dyspnoea 16 (22.2%) 12 (27.9%) .492 17 (23.6%) 17 (39.5%) .070
Insomnia 10 (13.9%) 6 (14.0%) .992 15 (20.8%) 8 (18.6%) .773
Appetite loss 1 (1.4%) 1 (2.3%) .710 1 (1.4%) 1 (2.3%) .710
Constipation 3 (4.2%) 5 (11.6%) .128 3 (4.2%) 4 (9.3%) .265
Diarrhea 4 (5.6%) 5 (11.6%) .241 21 (29.2%) 10 (23.3%) .489
Financial difficulties 15 (20.8%) 11 (25.6%) .556 14 (19.4%) 10 (23.3%) .627
Abbreviation: EORTC QLQ-C30 Z European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core.
Smaller values indicate lower prevalence of clinically important problems (ie, functional impairment) or symptoms.
Exercise group (n Z 72); control group (n Z 43).
Table 5 EORTC QLQ-PR25 symptom and functional scales at baseline and after 6 months of exercise or usual care (control)
Baseline 6 months Estimated mean change from
baseline to 6 months
Adjusted between-group
difference in mean change from
baseline to 6 months*
Mean (SD) Mean (SD) Mean (95% CI) P valuey Coefficient 95% CI P value
Urinary symptoms e2.2 e8.4 to 3.9 .473
Exercise 14.5 (12.8) 21.3 (18.8) 6.9 (3.2-10.6) <.001
Control 17.2 (16.3) 26.1 (18.9) 9.1 (4.3-14.0) <.001
Incontinence aid e21.7 e44.0 to 0.6 .056
Exercise (n Z 5) 13.3 (18.3) 0.0 (0.0) e8.3 (e22.5 to 5.9) .240
Control (n Z 4) 25.0 (31.9) 41.7 (16.7) 13.4 (e3.7 to 30.4) .119
Bowel symptoms 0.5 e3.5 to 4.5 .801
Exercise 2.2 (5.4) 5.9 (9.6) 3.8 (1.3-6.2) .003
Control 4.4 (8.0) 7.6 (10.6) 3.2 (0.1-6.4) .046
Hormonal treatment-related symptoms 1.1 e2.6 to 4.9 .552
Exercise 9.4 (9.9) 16.9 (13.8) 6.9 (4.6-9.1) <.001
Control 10.3 (9.9) 15.9 (12.4) 5.7 (2.8-8.7) <.001
Sexual activity 4.8 e4.7 to 14.3 .323
Exercise 22.2 (24.4) 20.1 (20.5) e2.3 (e8.2 to 3.5) .427
Control 19.0 (21.7) 12.0 (21.0) e7.1 (e14.7 to 0.42) .064
Sexual functioning 10.0 e20.4 to 40.3 .512
Exercise (n Z 10) 51.9 (27.3) 50.8 (21.3) e9.2 (e25.6 to 7.2) .265
Control (n Z 3) 72.2 (34.7) 63.9 (34.7) e19.2 (e44.7 to 6.3) .137
Abbreviations: BMI Z body mass index; CI Z confidence interval; EORTC QLQ-PR25 Z European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire prostate cancer module; SD Z standard deviation.
Exercise group n Z 72, control group n Z 43, unless indicated otherwise.
* Generalised linear mixed model analysis adjusted for BMI and hypertension status.
y Estimated mean change and corresponding P values are based on adjusted mixed model analysis using a sequential Bonferroni adjusted sig-
nificance level of 0.05.
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group; and (3) the exercise intervention did not appear to
exacerbate prostate cancer-specific, patient-reported
health outcomes of urinary and bowel symptoms overall
compared with the control group, although increased
reporting of diarrhea was statistically significant only in
the exercise but not the control group.
Prostate cancer treatment is associated with a range of
side effects that can affect a patient’s quality of life. In
men with prostate cancer undergoing radiation therapy
with or without ADT, common side effects include un-
favorable body composition changes, fatigue, urinary and
bowel symptoms, and sexual problems.26-28 It has been
previously demonstrated that exercise can be an effective
treatment to counteract some of these side ef-
fects.14,15,25,29 For example, from the previous studies on
patients included in this secondary analysis we reported
that combining resistance training and impact loading
attenuated bone loss and preserved muscle mass in pa-
tients undergoing ADT.14,15 However, less information is
available for patients with prostate cancer treated specif-
ically with radiation therapy alone or in combination with
ADT. To date, the largest randomized controlled trial of
patients with prostate cancer initiating radiation therapy
with or without ADT has been conducted by Segal et al.30
They investigated the effect of 24 weeks of aerobic or
resistance exercise in 121 patients with prostate cancer on
fatigue (primary outcome), quality of life, and physical
fitness among other outcomes. Both exercise interventions
mitigated fatigue compared with a usual care control
group, and resistance training also improved quality of
life.30 In line with these results, the exercise intervention
of the present study resulted in improved physical per-
formance and maintenance of fatigue levels in the exer-
cise group, whereas fatigue was significantly increased in
the control group at 6 months compared with baseline
values. Furthermore, the adjusted mean change of 7.4
points in the control group is clinically important,
although modest.31
Interestingly, a substantial increase in the prevalence of
clinically important pain was observed in the control
group at 6 months (ie, after the intervention), which was
not seen in the exercise group. Furthermore, although not
statistically significant between groups, the within-group
mean change of 5.2 points in the pain score in the control
group is clinically important, albeit a modest change.
Unfortunately, the EORTC QLQ-C30 does not specify
the type or location of pain but assesses pain in general
and whether it interferes with daily activities. Thus,
identifying how exercise might have affected pain in the
present study was not possible. Griffith et al32 also
assessed pain in a mixed cancer cohort (55.6% prostate
cancer) randomized to either a home-based walking pro-
gram or usual care. Although an increased exercise dose
was associated with decreased pain in their study, there
was no significant difference in the change of pain scores
between the 2 groups.32 More research is required to
determine whether exercise significantly affects pain and
what specific exercise prescription is most appropriate.
In contrast to previous studies,17,33 the multicompo-
nent exercise program did not prevent or improve
treatment-related urinary and bowel toxicities, but there
was a trend for use of incontinence aids to be less of a
problem for men in the exercise group. However, only a
limited number of patients reported wearing an inconti-
nence aid, which may have affected the results. One
possible explanation for the nonsignificant effect of ex-
ercise in our study for urinary and bowel symptoms could
be that outcomes were assessed by patient self-report
using validated questionnaires as opposed to clinician
assessment at weekly treatment review as in the study by
Kapur et al.17 However, Dieperink et al33 also used a self-
report questionnaire to assess treatment-related adverse
effects in patients with prostate cancer in a multidisci-
plinary rehabilitation program and found that exercise
resulted in improvements in urinary scores compared with
a usual care control group. It is important to note, how-
ever, that the study by Dieperink et al33 was conducted
postradiation and, thus, patients may have presented with
a different toxicity profile compared with the present
analysis. It is also noteworthy that urinary and bowel
problems overall were not reported by patients in the
exercise group as being worse than in the control group,
except for diarrhea, which, despite increasing in both
groups, was only significant in the exercise group. This
provides early evidence to counter the perception18,19 that
exercise, in particular resistance and impact training, may
exacerbate urinary and bowel issues and requires further
targeted research.
Erectile dysfunction is a common problem after treat-
ment in men with prostate cancer.34 In a study comparing
sexual function in men with localized prostate cancer on
active surveillance with patients receiving radical therapy,
56% to 60% of men who received radiation therapy were
sexually inactive as a result of erectile dysfunction.35
Furthermore, among patients in the radiation therapy
group who were sexually active, 73% to 76% had prob-
lems achieving or maintaining an erection.35 It has pre-
viously been shown that exercise maintains sexual
activity in men with prostate cancer undergoing ADT.36
However, in this previous trial,36 less than 30% of men
received concomitant radiation, limiting the ability to
detect a compounding effect of ADT and radiation on
sexual activity and function. Despite all patients in the
current trial receiving ADT and radiation, sexual activity
was approximately the same before and after the inter-
vention in the exercise group compared with the usual
care control group that showed a trend for a decrease in
sexual activity. Dahn et al37 evaluated the relationship
between physical activity and sexual functioning in men
with localized prostate cancer who had undergone radia-
tion therapy in the previous 18 months and observed that
increased physical activity was significantly associated
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with better sexual functioning. In the present analysis,
there was, however, no significant difference between
groups in sexual functioning, although the sexual func-
tioning score decreased by 8.3 points (unadjusted within-
group difference of mean scores) in the control group
compared with similar pre- and postintervention scores in
the exercise group. However, owing to the structure of the
questionnaire we used in this analysis, which requires
patients to answer questions related to sexual functioning
only if they had been sexually active within the last 4
weeks of answering the questionnaire, data were only
available for 13 patients (11%).
As expected, the exercise intervention had a significant
effect on multiple indices of upper and lower body muscle
strength and aerobic capacity. These improvements
included increased physical performance in the 400-meter
walk as well as 1RM strength in several muscle groups of
the upper and lower body, specifically the legs, back, and
chest. Preserving, or improving, physical function and
performance is important given its association with pa-
tient outcomes and survival. For example, slower 400-
meter walk was associated with increased mortality,
incident cardiovascular disease, mobility limitation, and
disability in a cohort study of 3075 community-dwelling
older adults.38 Furthermore, in a systematic review of
studies of patients with cancer, poorer physical perfor-
mance was associated with treatment-related complica-
tions and decreased survival.39 Hence, engaging in
exercise and physical activity should be recommended to
patients with cancer commencing treatment, particularly if
patients already present with decreased performance and
ability to perform daily tasks.
The present study has several strengths and limitations
that are worth mentioning. Our study reports on a large
sample of 115 men diagnosed with prostate cancer un-
dergoing both radiation therapy and ADT. Moreover,
patients followed a well-supervised clinic-based exercise
program ensuring appropriate training progression to
facilitate optimal training outcomes over the 6-month
intervention period. A limitation of this study is that the
thresholds for clinical importance used in the present
analysis to calculate the prevalence rates of clinically
important problems/symptoms are not prostate cancer-
specific. However, the cancer patient population in the
study by Giesinger et al23 upon which the thresholds are
based nevertheless consisted of 9.7% patients with pros-
tate cancer.
Conclusions
Exercise during concomitant hormone and radiation
treatment for men with prostate cancer may mitigate some
adverse changes in patient-reported fatigue, physical
functioning, and possibly sexual activity. In addition, the
prevalence of clinically important pain was lower in the
exercise group at 6 months compared with the control
group. Although there was no mediating effect on patient-
reported urinary, bowel, or hormonal treatment-related
symptoms overall, exercise did not exacerbate these is-
sues, with the exception of diarrhea. Given that exercise
appears to be an effective countermeasure to several
treatment-related adverse effects, patients undergoing ra-
diation therapy and ADT should be encouraged by their
oncologist to engage in physical exercise during
treatment.
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